Neratinib and entinostat combine to rapidly reduce the expression of K-RAS, N-RAS, Gα(q) and Gα(11) and kill uveal melanoma cells

There is no efficacious standard of care therapy for uveal melanoma. Unlike cutaneous disease, uveal melanoma does not exhibit RAS mutations but instead contains mutations with ~90% penetrance in either Gα(q) or Gα(11). Previously we demonstrated that neratinib caused ERBB1/2/4 and RAS internalizati...

Täydet tiedot

Tallennettuna:
Bibliografiset tiedot
Julkaisussa:Cancer Biol Ther
Päätekijät: Booth, Laurence, Roberts, Jane L., Sander, Cindy, Lalani, Alshad S., Kirkwood, John M., Hancock, John F., Poklepovic, Andrew, Dent, Paul
Aineistotyyppi: Artigo
Kieli:Inglês
Julkaistu: Taylor & Francis 2018
Aiheet:
Research Paper
Linkit:https://ncbi.nlm.nih.gov/pmc/articles/PMC6606002/
https://ncbi.nlm.nih.gov/pubmed/30571927
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1080/15384047.2018.1551747
Tagit: Lisää tagi
Ei tageja, Lisää ensimmäinen tagi!

Samankaltaisia teoksia